1.上海中医药大学附属市中医医院(上海 200070)
2.上海中医药大学附属曙光医院(上海 201203)
3.上海开元骨科医院(上海 200120)
周峰峰,男,硕士,住院医师,主要从事中医肝病研究
卓蕴慧,主任医师,硕士生导师;E-mail: huihuiz1688@hotmail.com
杨昌琨,男,博士,主治医师,主要从事中医肝病研究
纸质出版日期:2024-05-25,
收稿日期:2022-06-20,
修回日期:2024-04-12,
扫 描 看 全 文
周峰峰,陈羽,蔡浩亮等.穴位埋线治疗非酒精性脂肪性肝病的临床疗效观察[J].上海中医药大学学报,2024,38(03):45-49.
ZHOU Fengfeng,CHEN Yu,CAI Haoliang,et al.Observation on clinical efficacy of acupoint catgut embedding therapy on non⁃alcoholic fatty liver disease[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(03):45-49.
周峰峰,陈羽,蔡浩亮等.穴位埋线治疗非酒精性脂肪性肝病的临床疗效观察[J].上海中医药大学学报,2024,38(03):45-49. DOI: 10.16306/j.1008-861x.2024.03.007.
ZHOU Fengfeng,CHEN Yu,CAI Haoliang,et al.Observation on clinical efficacy of acupoint catgut embedding therapy on non⁃alcoholic fatty liver disease[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(03):45-49. DOI: 10.16306/j.1008-861x.2024.03.007.
目的
2
探讨穴位埋线治疗非酒精性脂肪性肝病(NAFLD)临床疗效。
方法
2
纳入非酒精性脂肪性肝病患者130例,采用随机数字表分为普通针刺组和穴位埋线组,每组各65例。两组患者分别于0、1、3、6月检测患者血脂、肝功能等指标,对比0、6月核磁共振成像(MRI)肝脏脂肪含量定量分析变化情况,评估穴位埋线的治疗效果;于0、3、6月检测患者血浆脂联素(ADP)、过氧化物酶体增殖激活α受体(PPAR-α)活性,观察血脂和ADP、PPAR-α活性变化的相关性。
结果
2
①两组患者治疗后各阶段与治疗前比较,肝功能、血脂水平均有改善,且穴位埋线组疗效优于普通针刺组(
P
<
0.01);②ADP、PPAR-α与治疗前比较显著上升(
P
<
0.01),治疗后两组ADP、PPAR-α水平比较差异显著(
P
<
0.01);③治疗后,两组MRI肝脏脂肪含量定量分析比较差异显著(
P
<
0.05),穴位埋线组MRI肝脏脂肪含量定量分析明显优于普通针刺组。
结论
2
穴位埋线疗法能有效改善肝脏脂肪沉积,且疗效优于普通针刺。
Objective: To evaluate the clinical efficacy of acupoint catgut embedding in the treatment of non-alcoholic fatty liver disease (NAFLD).
Methods
2
A total of 130 patients with NAFLD were divided into ordinary acupuncture group and acupoint catgut embedding group by random number table, 65 cases in each group. Blood lipid, liver function and other indicators of both groups were detected at 0, 1, 3 and 6 months respectively, and the changes of quantitative analysis of liver fat content by MRI at 0 and 6 months were compared to evaluate the therapeutic effect of acupoint catgut embedding. At 0, 3 and 6 months, the activities of the patients' ADP and PPAR-α were detected, and the correlation between blood lipid and the changes of ADP and PPAR-α activities was observed.
Results
2
①Compared with those before treatment, the liver function and blood lipid levels of the two groups were improved at each stage after treatment, and the therapeutic effect of the acupoint catgut embedding group was better than that of the ordinary acupuncture group (
P
<
0.01). ②ADP and PPAR-α were significantly increased compared with those before treatment (
P
<
0.01), and there were significant differences in ADP and PPAR-α levels between the two groups after treatment (
P
<
0.01). ③After treatment, there was a significant difference in the quantitative analysis of MRI liver fat content between the two groups (
P
<
0.05), and the quantitative analysis of MRI liver fat content in the acupoint catgut embedding group was significantly superior than that in the ordinary acupuncture group.
Conclusion
2
Acupoint catgut embedding therapy can effectively improve liver fat deposition, and the efficacy is better than that of ordinary acupuncture.
非酒精性脂肪性肝病穴位埋线针灸临床观察
non-alcoholic fatty liver diseaseacupoint catgut embeddingacupunctureclinical observation
PAOLELLA G, MANDATO C, PIERRI L, et al. Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(42): 15518-15531.
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26 (2): 120-124.
Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 中华肝脏病杂志, 2018(3): 195-203.
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease :A 2018 update versim[J]. Chinese Journal of Hepatology, 2018(3): 195-203.
郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社, 2002: 364-365.
ZHENG X Y. Guiding Principles for Clinical Research of New Drugs of Traditional Chinese Medicine (trial implementation)[M]. Beijing:China Medical Science Press,2002:364-365.
TILG H, TARGHER G. NAFLD-related mortality: simple hepatic steatosis is not as "benign" as thought[J]. Gut, 2021, 70(7): 1212-1213.
段晓燕, 范建高. 2011亚太肝病学会非酒精性脂肪性肝病纪要[J]. 临床肝胆病杂志, 2011, 27 (5): 458-461, 470.
DUAN X Y, FAN J G. Nonalcoholic fatty liver disease (NAFLD): summary of the 2011 conference of the Asia Pacific Association for the Study of the Liver (APASL)[J]. Journal of Clinical Hepatology, 2011, 27 (5): 458-461, 470.
DAY C P, JAMES O F. Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845.
DE LUCA C, OLEFSKY J M. Inflammation and insulin resistance[J]. FEBS Lett, 2008, 582(1): 97-105.
黄鸿娜, 黄晶晶, 毛德文, 等. 八髎穴埋线联合祛瘀化浊汤治疗非酒精性脂肪性肝炎的临床研究[J]. 现代中西医结合杂志, 2017, 26(3): 272-274.
HUANG H N, HUANG J J, MAO D W, et al. The clinical study focuses on the treatment of non-alcoholic steatohepatitis using Baliao Acupoint embedding and Qu yu Hua zhuo Decoction[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2017, 26(3): 272-274.
龚秀杭, 陈芝芸, 严茂祥. 穴位埋线治疗大鼠非酒精性脂肪肝的实验研究[J].中华中医药学刊, 2011, 29(3): 543-544.
GONG X H, CHEN Z Y, YAN M X. Experimental study on the use of acupoint catgut embedding for the treatment of nonalcoholic fatty liver in rats[J]. Chinese Archives of Traditional Chinese Medicine, 2011, 29(3): 543-544.
周晓玲, 谢胜, 侯秋科. 穴位埋线对非酒精性脂肪性肝病大鼠SREBP-1表达的影响[J]. 中国中医急症, 2011, 20(6): 902-903, 908.
ZHOU X L, XIE S, HOU Q K. Influence of Point Embedding Therapy on Expression of Sterol Regulatory Element Binding Protein-1 of Rats with Nonalcoholic Fatty Liver Disease[J]. Journal of Emergency in Traditional Chinese Medicine, 2011, 20(6): 902-903, 908.
温秀梅, 陈芝芸, 龚秀杭, 等. 穴位埋线对非酒精性脂肪肝模型大鼠血清瘦素和脂联素的影响[J]. 山东中医杂志, 2012, 31(2): 128-129.
WEN X M, CHEN Z Y, XUE X H, et al. Effect of acupoint catch-embedding on serum leptin and adiponectin in rats with nonalcoholic fatty liver[J]. Shandong Journal of Traditional Chinese Medicine, 2012, 31(2): 128-129.
SERRANO A, PAVÓN N F J, SUAREZ J, et al. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals[J]. Am J Physiol Endocrinol Metab, 2012, 302(7): E817-E830.
LISS K H, FINCK B N. PPARs and nonalcoholic fatty liver disease[J]. Biochimie, 2017, 136: 65-74.
SINHA R A, RAJAK S, SINGH B K, et al . Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk[J]. Int J Mol Sci, 2020, 21(7): 2391.
WAHLI W, MICHALIK L. PPARs at the crossroads of lipid signaling and inflammation[J]. Trends Endocrinol Metab, 2012, 23(7): 351-363.
KE Y, XU C, LIN J, et al. Role of Hepatokines in Non-alcoholic Fatty Liver Disease[J]. J Transl Intern Med, 2019, 7(4): 143-148.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构